Gossamer Bio, Inc.
GOSS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001728117
No open-market purchases or sales by Gossamer Bio, Inc. insiders were filed in the last 90 days; 171 institutions reported holding it in 13F filings for Q2 2026, worth $60.8M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:06 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $170.4M (351.5% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 17, 2026 | Mar 13, 2025 | Mar 5, 2024 | Mar 17, 2023 | Mar 3, 2022 |
| Revenue | $48.5M | $114.7M | – | – | – |
| Operating expenses | $219.2M | $174.6M | $183.8M | $218.6M | $216.1M |
| Research and development | $174.1M | $138.5M | $135.3M | $170.9M | $170.3M |
| Selling, general and administrative | $37.6M | $36.1M | $38.5M | $47.6M | $45.8M |
| Operating income | -$170.7M | -$59.9M | -$183.8M | -$218.6M | -$216.1M |
| Interest expense | – | – | $13.5M | $13.9M | $19.4M |
| Income tax | -$88.0K | $893.0K | – | – | – |
| Net income | -$170.4M | -$56.5M | -$179.8M | -$229.4M | -$234.0M |
| EPS, basic | $-0.75 | $-0.25 | $-1.18 | $-2.71 | $-3.13 |
| EPS, diluted | $-0.75 | $-0.25 | $-1.18 | $-2.71 | $-3.13 |
| Weighted shares, basic | 228.5M | 226.2M | 152.6M | 84.6M | 74.8M |
| Weighted shares, diluted | 228.5M | 226.2M | 152.6M | 84.6M | 74.8M |
| Margins and growth | |||||
| Operating margin | -352.2% | -52.2% | – | – | – |
| Net margin | -351.5% | -49.3% | – | – | – |
| Revenue growth, year over year | −57.7% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 17, 2026 | Mar 13, 2025 | Mar 5, 2024 | Mar 17, 2023 | Mar 3, 2022 |
| Cash and equivalents | $37.7M | $46.1M | $32.1M | $112.0M | $183.4M |
| Short-term investments | $99.2M | $248.4M | $264.3M | $143.7M | $141.8M |
| Accounts receivable | $12.2M | $5.34M | – | – | – |
| Total current assets | $167.6M | $309.9M | $306.5M | $261.9M | $331.8M |
| Property, plant and equipment | $64.0K | $10.0K | $1.65M | $3.98M | $5.32M |
| Total assets | $172.2M | $315.3M | $311.9M | $272.4M | $343.7M |
| Accounts payable | $5.96M | $2.32M | $5.53M | $1.46M | $3.24M |
| Short-term debt | – | $0 | $11.6M | $11.6M | – |
| Total current liabilities | $63.4M | $45.0M | $51.6M | $49.2M | $39.9M |
| Long-term debt | – | $0 | $814.0K | $12.0M | $29.1M |
| Total liabilities | $295.0M | $285.8M | $249.1M | $260.4M | $222.2M |
| Shareholders' equity | -$122.8M | $29.5M | $62.8M | $12.1M | $121.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 17, 2026 | Mar 13, 2025 | Mar 5, 2024 | Mar 17, 2023 | Mar 3, 2022 |
| Operating cash flow | -$171.3M | -$3.47M | -$159.2M | -$187.0M | -$188.9M |
| Capital expenditures | $79.0K | $0 | $0 | $410.0K | $1.55M |
| Free cash flow | -$171.3M | -$3.47M | -$159.2M | -$187.4M | -$190.4M |
| Depreciation and amortization | $24.0K | $833.0K | $1.61M | $1.83M | $1.74M |
| Stock-based compensation | $10.6M | $20.6M | $28.5M | $42.6M | $32.0M |
| Investing cash flow | $156.4M | $29.0M | -$111.0M | -$1.03M | -$117.4M |
| Financing cash flow | $6.42M | -$11.5M | $190.2M | $117.1M | $3.33M |
| Net change in cash | -$8.34M | $14.0M | -$79.9M | -$71.5M | -$303.2M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 21.8% | 18.0% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 8, 2026 | 488.8M | +115.0% | SEC |
| May 12, 2026 | 234.7M | +3.3% | SEC |
| Mar 10, 2026 | 234.7M | +3.3% | SEC |
| Oct 31, 2025 | 231.5M | +2.1% | SEC |
| Jul 31, 2025 | 227.4M | +0.5% | SEC |
| May 12, 2025 | 227.3M | +0.5% | SEC |
| Mar 6, 2025 | 227.2M | +0.7% | SEC |
| Nov 4, 2024 | 226.6M | +0.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-80 in Q3 2026.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.